Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Assembly Biosciences Inc(ASMB)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ASMB
09/25/2026: ASMB (1-star) is currently NOT-A-BUY. Pass it for now.
Assembly Biosciences is a clinical-stage biotechnology company focused on developing novel small-molecule therapies for viral infections, including hepatitis B and herpesviruses. Its core strength lies in its specialized research platform and a strategic, long-standing partnership with Gilead Sciences that provides essential funding and validation. The primary growth story centers on the successful clinical advancement of its next-generation antiviral pipeline. However, the company faces significant execution and competitive risks, as it currently lacks commercial revenue and operates in a high-stakes R&D sector. This stock may suit investors with a high risk tolerance and an interest in biotech innovation, requiring careful monitoring of future clinical data readouts.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-risk, high-reward exposure to biotech innovation but lacks current commercial product growth. |
| Momentum investor | Strong fit while signal remains positive | Momentum investors may find opportunity during clinical trial news cycles and positive data releases. |
| Value investor | Weak fit | Standard valuation metrics like P/E are not applicable due to the lack of steady earnings. |
| Dividend investor | Weak fit | The company pays no dividends and requires cash for R&D. |
| Low-risk investor | Weak fit | High volatility associated with clinical-stage biotech makes this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stock prices are often sensitive to binary clinical trial results. |
| Valuation risk | Medium / high | Without commercial revenue, valuation is speculative and based on future potential. |
| Competition risk (Large Pharma) | High | The company faces intense competition from better-capitalized pharmaceutical firms. |
| Business quality | Medium | The business relies on scientific innovation rather than established franchise quality. |
| Dividend income | Low / none | No income is generated for shareholders. |
| Execution risk | High | Failure to advance clinical programs can result in significant loss of shareholder value. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 47.84% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 481.73M USD | Price to earnings Ratio 19.08 | 1Y Target Price 52 |
Price to earnings Ratio 19.08 | 1Y Target Price 52 | ||
Volume (30-day avg) 382.4K shares | Beta 1.13 | 52 Weeks Range 21.80 - 39.71 | Updated Date 09/25/2026 |
52 Weeks Range 21.80 - 39.71 | Updated Date 09/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.24 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Strategic Research Collaborations | Milestone payments and research funding from partners like Gilead Sciences. | The company is paid for its research success and progress by larger partners. |
Valuation
Trailing PE 19.08 | Forward PE 500 | Enterprise Value 200.17M | Price to Sales(TTM) 6.44 |
Enterprise Value 200.17M | Price to Sales(TTM) 6.44 | ||
Enterprise Value to Revenue 2.68 | Enterprise Value to EBITDA 0.42 | Shares Outstanding 20.36M | Shares Floating 9.17M |
Shares Outstanding 20.36M | Shares Floating 9.17M | ||
Percent Insiders 27.66 | Percent Institutions 69.5 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Assembly Biosciences Inc
Exchange NASDAQ | Headquarters South San Francisco, CA, United States | ||
IPO Launch date 2010-12-17 | CEO, President & Director Mr. Jason A. Okazaki J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 73 | Website https://www.assemblybio.com |
Full time employees 73 | Website https://www.assemblybio.com | ||
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.